(方土方)博醫療(02216.HK)熱蒸汽治療系統進入內地臨床應用階段
(方土方)博醫療-B(02216.HK)公布,已完成其熱蒸汽治療系統InterVapor在中國獲批上市後的首批手術,標誌著InterVapor正式在中國進入臨床應用階段。首批兩台手術分別由中國科學院大學深圳醫院呼吸內科龍發教授團隊以及西安國際醫學中心胸科醫院呼吸與危重症醫學科歐陽海峰教授團隊完成。
公司指,其自主研發的InterVapor產品於3月正式獲得國家藥監局批准上市,是中國及全球首個獲得NMPA批准的用於治療慢阻肺的熱蒸汽能量消融系統,為國內重度和極重度慢阻肺患者帶來介入治療方案,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.